What is the clinical evidence from this study?

Study design: Observational. Population: Paralytic poliomyelitis (n=138). Intervention: Oral polio vaccine (OPV) vs. Subsequent doses. Primary outcome: Frequency of vaccine-associated paralytic poliomyelitis.

March 13, 1987JAMA

Vaccine-Associated Paralytic Poliomyelitis

Q: What does this research mean for the field?

The first dose of oral polio vaccine (OPV) carries a significantly higher risk of vaccine-associated paralytic poliomyelitis (1 case per 520,000 doses) compared to subsequent doses (1 per 12.3 million doses), although the overall risk remains very small. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

View Full Paper

Ask AI

Bookmark

Key result

The first dose of oral polio vaccine (OPV) carried a higher risk of vaccine-associated paralytic poliomyelitis (1 case per 520,000 doses) compared to subsequent doses (1 per 12.3 million doses).

Why the study?

What is the frequency and risk of vaccine-associated paralytic poliomyelitis following oral polio vaccine administration?

Key Points

To evaluate the incidence, distribution, and dose-specific risks of vaccine-associated paralytic poliomyelitis in the United States following oral polio vaccine administration.
Analyzed national surveillance data encompassing 138 reported cases of paralytic poliomyelitis in the United States between 1973 and 1984 (N=138).
Categorized 105 vaccine-associated cases by recipient status, contact exposure, immune deficiency status, and dose sequence relative to distributed vaccine doses.
Of 105 vaccine-associated cases, 35 occurred in oral polio vaccine (OPV) recipients, 50 in household or community contacts, 14 in immune-deficient individuals, and 6 in persons without known vaccine exposure.
The initial vaccine dose accounted for 94% (33/35) of recipient cases, 82% (41/50) of contact cases, and 36% (5/14) of immune-deficient cases.
Overall incidence was one case per 2.6 million doses distributed, with a significantly higher rate for the first dose (one case per 520,000 doses) compared to subsequent doses (one case per 12.3 million doses).

Study Design

Type

Observational (n=138)

Structured PICO

What is the frequency and risk of vaccine-associated paralytic poliomyelitis following oral polio vaccine administration?

Population

138 cases of paralytic poliomyelitis reported in the United States from 1973 through 1984

Intervention

Oral polio vaccine (OPV)

Outcome

Vaccine-associated paralytic poliomyelitissafety

Vaccine-associated paralytic poliomyelitis is a rare complication of the oral polio vaccine, with the greatest risk occurring after the first dose.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Suggests first-dose monitoring with OPV; leaves open need for prospective validation in modern schedules.

Cite This Study

Benjamin M. Nkowane (1987) conducted an observational in Paralytic poliomyelitis (n=138). Oral polio vaccine (OPV) vs. Subsequent doses was evaluated on Frequency of vaccine-associated paralytic poliomyelitis. The first dose of oral polio vaccine (OPV) carried a higher risk of vaccine-associated paralytic poliomyelitis (1 case per 520,000 doses) compared to subsequent doses (1 per 12.3 million doses).

synapsesocial.com/papers/6a16a442b13aec50ea6b5154 https://doi.org/10.1001/jama.1987.03390100073029

View Full Paper

Ask AI

Bookmark

Vaccine-Associated Paralytic Poliomyelitis

Key Points

Study Design

Structured PICO

Discussion

Implication

Cite This Study

Vaccine-Associated Paralytic Poliomyelitis

Key Points

Study Design

Structured PICO

Discussion

Implication

Cite This Study

Also Consider

Also Consider